Catalyst Pharmaceuticals, Inc.
CPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.14 | -1.54 | 0.21 | -0.38 |
| FCF Yield | 9.68% | -3.07% | 6.03% | 8.48% |
| EV / EBITDA | 8.41 | 13.81 | 15.99 | 10.16 |
| Quality | ||||
| ROIC | 20.21% | 16.63% | 25.38% | 18.61% |
| Gross Margin | 86.00% | 78.77% | 83.94% | 84.46% |
| Cash Conversion Ratio | 1.46 | 2.01 | 1.40 | 1.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.92% | 41.41% | 21.62% | 11.24% |
| Free Cash Flow Growth | 535.61% | -147.34% | 95.48% | 31.82% |
| Safety | ||||
| Net Debt / EBITDA | -2.21 | -1.12 | -2.89 | -3.20 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.52 | 5.40 | 5.05 | 2.78 |
| Cash Conversion Cycle | 64.23 | 52.72 | 48.42 | 102.52 |